FT516 in Subjects With Advanced Hematologic Malignancies
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
Acute Myelogenous Leukemia|B-cell Lymphoma
DRUG: FT516|DRUG: Rituximab|DRUG: Obinutuzumab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|DRUG: Bendamustine
The incidence of subjects with Dose Limiting Toxicities within each dose level cohort., Day 29|Incidence, nature, and severity of AEs, of FT516 as monotherapy in r/r AML and in combination with rituximab or obinutuzumab in r/r B-cell lymphoma., Up to 5 years
Investigator-assessed anti-tumor activity of FT516 as monotherapy in r/r AML and in combination with rituximab or obinutuzumab in r/r B-cell lymphoma., Cycle 2 Day 29|FT516 pharmacokinetic data, Percentage of donor DNA measured at each timepoint, Cycle 1 and Cycle 2 Study Days: 1, 2, 4, 8, 11, 15, 18, 22, 29, and Cycle 2 Day 43 and Cycle 2 Day 57.
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.